Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens.
What the Market Looks Like?
The global HPV testing and Pap test market is projected to reach USD 4.52 billion by 2020 from USD 3.29 billion in 2015, at a CAGR of 6.6% from 2015 to 2020.
Cervical cancer is considered to be the fourth most prevalent forms of cancer globally, and is the most common cause of death among women (Source: Global Cancer Facts and figures). It has been estimated that 527,624 new cases of cervical cancer have emerged worldwide, while 265,653 women died due to cervical cancer in 2012.
Download PDF Brochure @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371
What are Key Trends in the Market?
The growth of the HPV Testing and Pap Test Market is primarily influenced by the following factors:
Increasing Number of Cervical Cancer Cases and Growing Aging Population
Increasing Awareness of Cervical Cancer Screening Programs
Government Initiatives and Funding
The Papanicolaou test (Pap test) is a screening test used to detect pre-cancerous cells in the endocervical canal of the female reproductive system. Pre-cancerous cells might change into cancerous cells, if they are not diagnosed at an early stage. Pap tests are usually used to screen for cervical cancer, but sometimes vaginal cancer cells can also be detected on a Pap test.
Read more about HPV Testing Market@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371